The European Patent Office Votes to Modernize the ‘10-Day Rule’
Brownstein Client Alert, Oct. 19, 2022
On Oct. 13, 2022, the Administrative Council of the European Patent Office (EPO) voted to change Rule 126(2) of the EPC (the “10-day rule”). This change comes as part of the annual revision cycle for the EPC and PCT-EPO guidelines. While the revised rule was preliminarily approved in May 2022, the package of rule changes was officially passed during the second meeting of the Standing Advisory Committee before the EPO.
The 10-day rule was originally enacted in 1973 to account for unknown delays in physical mailing of EPO correspondence to patent applicants. Under the rule, communications from the EPO are deemed received by an applicant 10 days from the mailing date of such communications, effectively extending deadlines triggered and/or imposed by the correspondence by 10 days.
The EPO voted to amend the 10-day rule as part of its effort “to adapt the rules of the EPC to the digital age.” New Rule 126(2) will deem the delivery of notifications and correspondence from the EPO as the date such notifications or correspondence was sent—consistent with current PCT and USPTO practice.
Implementation details on any transitional period(s) are not available as of this writing. However, applicants and practitioners alike representing applicants with EP applications and EP grants are well-advised to be aware of this change, especially considering practice changes resulting from, and necessitated by, the upcoming launch of the Unified Patent Court.
The New Rule 126(2) will be effective as of Nov. 1, 2023.
This document is intended to provide you with general information regarding changes to the EPO's Rule 126(2). The contents of this document are not intended to provide specific legal advice. If you have any questions about the contents of this document or if you need legal advice as to an issue, please contact the attorneys listed or your regular Brownstein Hyatt Farber Schreck, LLP attorney. This communication may be considered advertising in some jurisdictions. The information in this article is accurate as of the publication date. Because the law in this area is changing rapidly, and insights are not automatically updated, continued accuracy cannot be guaranteed.
Contributors:
Recent Insights
Read MoreFDA FY ’27 Budget Proposes Broad New Authorities and Reforms Across Food, Drugs and Medical Devices
Presentation | April 09, 2026Willful Infringement and Enhanced Damages, Current Trends to Inform your Damages Case
Client Alert | April 07, 2026Trump Admin Adjusts Tariffs for “Derivative Products” Containing Steel, Aluminum and Copper
Client Alert | April 03, 2026Critical Minerals Take Center Stage in Trump’s FY27 Budget Request
Client Alert | April 03, 2026Bulked-Up Defense, Slimmed-Down Domestic: Inside the FY 2027 Skinny Budget
Client Alert | April 03, 2026Trump Administration Announces Section 232 Tariffs on Pharmaceuticals
You have chosen to send an email to Brownstein Hyatt Farber Schreck or one of its lawyers. The sending and receipt of this email and the information in it does not in itself create and attorney-client relationship between us.
If you are not already a client, you should not provide us with information that you wish to have treated as privileged or confidential without first speaking to one of our lawyers.
If you provide information before we confirm that you are a client and that we are willing and able to represent you, we may not be required to treat that information as privileged, confidential, or protected information, and we may be able to represent a party adverse to you and even to use the information you submit to us against you.
I have read this and want to send an email.